← Back to Team

Dan Burgess

Venture Partner

Daniel burgessa banner
$asset->title

Dan joined SV Health Investors as a Venture Partner in 2014 and is Executive Chairman or Director of a number of SV and DDF portfolio companies. He is Executive Chairman of Pulmocide, a Director of Leiters and acting CEO and Director of Therini.

Prior to joining SV, Dan was Founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously, Dan was President and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.

Outside of SV, Dan holds external Board seats for Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Qpex Biopharma (Chairman), Cidara Therapeutics (Chairman, NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman Emeritus of Biocom, the life science industry association of California that represents more than 1,000 member companies. In his spare time, Dan is an avid golfer and also dabbles in the music industry.

Academic Credentials
AB, Economics, Stanford University; MBA, Harvard Business School

Portfolio